Le Lézard
Classified in: Health

CenterWatch Announces -- Developing Pharmaceutical Investigational Brochures & Annual Reports: Secrets to Practical Success and Total Compliance Webinar, Jan. 29, 2019


FALLS CHURCH, Va., January 18, 2019 /PRNewswire-PRWeb/ -- Developing Pharmaceutical Investigational Brochures & Annual Reports:
Secrets to Practical Success and Total Compliance
**A CenterWatch Webinar**
Tuesday, Jan. 29, 2019, 1:30 p.m. - 3:00 p.m. ET
https://store.centerwatch.com/p-543-developing-pharmaceutical-investigational-brochures-annual-reports-secrets-to-practical-success-and-total-compliance.aspx

Are accurate data, frequency, methods of administration and safety monitoring procedures included in the IB's?

Do the IB's provide investigators with a clear-cut understanding of the possible risks and adverse reactions, and of the specific tests, observations, and precautions that may be needed for a clinical trial to prevent patient litigation?

Is the IB updated with the latest information on trials in a timely manner to comply with IRB guidelines? Remember, it's the responsibility of the sponsor to keep the information in the IB up to date, including when the drug has received marketing approval and can be prescribed for use commercially.

In the annual report, is the complete description of any significant Phase 1 protocol modifications made during the previous year and not previously reported to the IND in a protocol amendment provided?

Tiffany Guckin, associate director of regulatory affairs, Invicro, will discuss the importance of both FDA IND annual reports and investigator brochures and the benefits of timely submissions and reviews as well as the content and structure. Over the course of 90-minutes she'll help attendees understand:

This presentation will highlight appropriate content to be included in annual reports and investigational brochures.

Meet Your Presenter
Tiffany Guckin, MS is the associate director of regulatory affairs; Invicro, a Konica Minolta company. She is a graduate from the University of Connecticut and Quinnipiac University. Tiffany is an experienced regulatory professional with more than 8 years in leading all regulatory operation aspects of IND filings and maintenance, as well as authoring Investigational Brochures (IBs) for early phase imaging research studies.    

Who Will Benefit

Webinar Details:
Developing Pharmaceutical Investigational Brochures & Annual Reports:
Secrets to Practical Success and Total Compliance
**A CenterWatch Webinar**
Tuesday, Jan. 29, 2019, 1:30 p.m. - 3:00 p.m. ET
https://store.centerwatch.com/p-543-developing-pharmaceutical-investigational-brochures-annual-reports-secrets-to-practical-success-and-total-compliance.aspx

Tuition:
$287 per site

Easy Ways to Register:
Online: https://store.centerwatch.com/p-543-developing-pharmaceutical-investigational-brochures-annual-reports-secrets-to-practical-success-and-total-compliance.aspx
By phone: 866-219-3440

About CenterWatch:
Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates.

SOURCE CenterWatch


These press releases may also interest you

at 11:51
U.S. Stem Cell, Inc. , a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, is pleased to announce its Chief Science Officer, Dr. Kristin Comella, will present at the 2018 Paleo...

at 11:44
Accelerate Diagnostics, Inc. today announced that it will report financial results for the first quarter of 2019 after the market close on Thursday, May 9, 2019. The Company's management will host a conference call at 4:30 p.m. ET that same day to...

at 11:44
The Annual General Meeting (AGM) of Immunovia AB (publ), corporate identity number 556730-4299 was held at Gamla Gästmatsalen in Medicon Village, Scheelevägen 2, Lund, Sweden on April 26 2019. A summary of the Meeting's resolutions follows:...

at 11:42
The 2016 annual general meeting of Orexo resolved on a long-term incentive plan for senior executives and key employees within the Orexo group ("LTIP 2016/2019"). Participants in LTIP 2016/2019 were granted share awards, entitling to shares in the...

at 11:28
Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection). The decision upholds an October 2017...

at 11:15
- Currently no approved treatments in the European Union for advanced cutaneous squamous cell carcinoma (CSCC) - CSCC is one of the most common skin cancers worldwide Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European...



News published on 18 january 2019 at 00:00 and distributed by: